Moving Helicobacter pylori vaccine development forward with bioinformatics and immunomics

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

This work was supported by NIH grant U19AI082642. L Moise has options in EpiVax, Inc., which is a privately owned vaccine design company located in Providence, RI, USA. AS De Groot is a senior officer and majority shareholder at EpiVax, Inc. These authors acknowledge that there is a potential conflict of interest related to their relationship with EpiVax and attest that the work contained in this research report is free of any bias that might be associated with the commercial goals of the company. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.